Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3833 - 3840 of 12141 results

Strategic Considerations at the Intersection of Patent and Trade Secret Protection
September 8, 2020| Video| Viewpoint

AB 5 “2.0” – California Tweaks its Independent Contractor Ban
September 8, 2020| Blog| Viewpoint

Kick the CCPA Compliance Program Back Into Gear
September 8, 2020| Blog| Viewpoint

COVID-19, the New School Year, and Working Parents
September 8, 2020| Blog| Viewpoint

Playing Fair: Protect Trade Secrets from Business Partners
September 8, 2020| Blog| Viewpoint

DOJ Antitrust Division Releases New Guidance on Merger Remedies for First Time Since Withdrawal of 2011 Policy Guide to Merger Remedies
September 8, 2020| Alert| Viewpoint

FCC Provides Additional Information on Making $100 million Available for Connected Care Services
September 4, 2020| Blog| Viewpoint

Bioethics in a Pandemic: Draft Framework for Equitable Allocation of COVID-19 Vaccine
September 4, 2020| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
